For the year ending 2025-12-31, CABA had -$80,980K decrease in cash & cash equivalents over the period. -$132,309K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -167,856 |
| Stock-based compensation | 20,939 |
| Depreciation | 1,646 |
| Non-cash finance lease expense | 11,697 |
| Non-cash operating lease expense | 3,671 |
| Accretion of operating lease liabilities | 532 |
| Amortization of discount on investments | 1,555 |
| Loss on foreign currency exchange rates | 225 |
| Prepaid expenses and other current assets | 2,559 |
| Other assets | 2,866 |
| Accounts payable | 1,550 |
| Accrued and other current liabilities | 7,432 |
| Lease liabilities | -4,227 |
| Accrued interest payable under finance lease | 291 |
| Net cash used in operating activities | -131,080 |
| Purchases of property and equipment | 1,229 |
| Purchases of investments | 99,037 |
| Proceeds from maturities of investments | 50,000 |
| Net cash (used in) provided by investing activities | -50,266 |
| Proceeds from the issuance of common stock, warrants and pre-funded warrants, net of issuance costs | 93,558 |
| Issuance of common stock from atm offering, net of sales agent commission and fees | 12,745 |
| Proceeds from the issuance of common stock under employee stock purchase plan | 291 |
| Proceeds from issuance of common stock in connection with the exercise of stock options | 14 |
| Principal payments on finance leases | 6,261 |
| Net cash provided by financing activities | 100,347 |
| Effect of exchange rate changes on cash and cash equivalents | 19 |
| Net decrease in cash and cash equivalents | -80,980 |
| Cash and cash equivalentsbeginning of year | 163,962 |
| Cash and cash equivalentsend of year | 82,982 |
Cabaletta Bio, Inc. (CABA)
Cabaletta Bio, Inc. (CABA)